Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death.

Like Comment
Despite approximately 4,400 unresectable U.S. cases annually, high-stage basal cell carcinoma (BCC) is ill-defined.Develop a tumor (T) staging system for BCC predicting metastasis/death and compare its performance to AJCC 8th edition (AJCC8) T staging.BWH T staging was developed from a previously published nested cohort of 488 primary BCCs. Tumors were staged via BWH and AJCC8 T staging systems and prediction of metastasis and/or death was compared.BWH and AJCC8 T staging systems both captured all metastases/deaths in high T stages (BWH T2; AJCC8 T3/T4). BWH T2 included 54% fewer cases ≥2cm compared to AJCC8 T3/T4. BWH had higher specificity (0.92 vs 0.80, p<0.001) and positive predictive value (24% vs 11%, p<0.001) for identifying cases at risk for metastasis/death, and C statistic was superior for BWH (p<0.001). BWH T2 ten-year cumulative incidence of metastasis/death was 37% (21-60%).Two-center cohort CONCLUSIONS: and Relevance: BWH and AJCC BCC staging both capture all metastases and deaths in upper stages. However, BWH does so in half the number of cases thus minimizing inappropriate up-staging. Risk of metastasis or death in BWH T2 BCC is sufficient to warrant surveillance for recurrence and clinical trials of adjuvant therapy.

View the full article @ Journal of the American Academy of Dermatology

Get PDF with LibKey


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following